Skip to Main Content

Two weeks ago, Merck (MRKpleasantly surprised investors by releasing promising top-line findings of a key lung cancer study for its Keytruda medicine. But a new survey suggests that some doctors remain squeamish about using the drug as a first-line treatment for their patients.

Specifically, 56 percent of 32 oncologists who were surveyed found the results encouraging, but are waiting for the complete study data to be released before they may use Keytruda as a first-line treatment, according to Bernstein analyst Tim Anderson, who commissioned the survey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.